PFE, SUPN Get FDA Nod, SNY Will Have To Wait Till Nov., Xenetic On The Move

Supernus Pharmaceuticals Inc. (SUPN) on Friday received tentative approval from the FDA for its Supplemental New Drug Application requesting a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults.

from RTT - Biotech http://ift.tt/2bXkBEO
via IFTTT